source
- Bristol Myers Squibb identifies cause of safety signal in lupus CAR‑T trialBristol Myers Squibb's cell therapy division is confronting ongoing safety challenges with its autoimmune CAR‑T program. The company says it has pinpointed the underlying cause of the safety signa…
- Biotech M&A slows sharply in Q3 as deal activity coolsThe third quarter saw a noticeable slowdown in biotech mergers and acquisitions after a busy first half of the year. Large upfront licensing agreements were fewer, and venture capital firms reduce…